Showing 19,641 - 19,660 results of 100,843 for search '(( 5 fold decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.94s Refine Results
  1. 19641

    table3_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  2. 19642

    table1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  3. 19643
  4. 19644

    image2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

    Published 2021
    “…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  5. 19645

    table2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  6. 19646

    image1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

    Published 2021
    “…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  7. 19647

    Table_1_Oral Zinc Sulfate for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis: A Meta-Analysis of Five Randomized Controlled Trials.DOCX by Xu Tian (179192)

    Published 2018
    “…We included five eligible studies involving 352 patients. Meta-analysis based on limited data revealed that oral zinc sulfate failed to decrease the incidence of chemotherapy-induced oral mucositis (RR [relative risk] = 0.52, 95% CI [confidence interval] = 0.17–1.64) as well as relieve chemotherapy-induced oral mucositits grade (RR = 0.62, 95% CI = 0.11–3.56; RR = 0.70, 95% CI = 0.29–1.71). …”
  8. 19648

    table4_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  9. 19649
  10. 19650

    Mean gizzard mass of birds directly after catch, during the first and second series of trials. by Thomas Oudman (401772)

    Published 2015
    “…After catch, all birds decreased gizzard mass, but group 1 had larger gizzards than group 2 during the first series of trials, and smaller gizzards during the second series (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0136144#pone.0136144.t002" target="_blank">Table 2</a>, models 1.1 to 1.5), showing that the manipulation of gizzard size was successful. …”
  11. 19651
  12. 19652
  13. 19653
  14. 19654
  15. 19655
  16. 19656
  17. 19657

    Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia by Taichi Kashiwagi (2430256)

    Published 2023
    “…NeuN+ neurons were significantly decreased by the hypoxic condition (Mean ± SEM, n = 4, *** p = 0.00028. …”
  18. 19658
  19. 19659

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  20. 19660

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”